Search

everythinglearnresearchcommunity

for

Search:↓

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

Topical tacalcitol can treat psoriasis by acting directly on skin cells.

Topical immunotherapy for alopecia areata may work by creating immune cell clusters in the skin.

IL-1α levels are higher in alopecia areata patients, suggesting a role in the disease.

Higher IL-15 levels are linked to more severe hair loss in alopecia areata.

IL-4 and IL-13 might play a role in a type of hair loss similar to alopecia areata.

Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.

VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.

IL-4 gene variation may increase the risk of alopecia areata in Turkish people.

FCO2 laser is a better treatment for alopecia areata than intralesional steroids.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

Certain immune cells in atopic dermatitis skin could be targeted for treatment.

Id2 gene helps keep hair follicle stem cells inactive.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

IL-27 can prevent hair loss in alopecia areata.

Certain immune cells, when activated by specific signals, can encourage hair growth.

The protein interleukin-1 alpha helps regenerate hair follicles and increase stem cell growth in mice.

Higher levels of IL-1R1 and hsa-miR-19b-3p may help diagnose and predict alopecia areata severity.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.

Interferon alfa-2a is effective for treating cutaneous T cell lymphoma but has significant side effects.

Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.